Physician profile
Bassel Salem
NPI 1164638185
$6,506.64
in general payments reported to CMS, 2019-2025
46 companies · $1,581 in 2025
The $1,581 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $541 · 2020: $313 · 2021: $793 · 2022: $1,462 · 2023: $1,055 · 2024: $762 · 2025: $1,581.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,374 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $23.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,374.41 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $23.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,788.54 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Novartis Pharmaceuticals Corporation | $442.69 | 2019-2025 | |
| Biogen, INC. | $423.12 | 2019-2025 | Vumerity, Tysabri |
| Lilly USA, LLC | $324.98 | 2019-2025 | Amyvid, Emgality, Kisunla |
| Ceribell, INC. | $268.71 | 2021 | |
| Mdd US Operations, LLC | $239.69 | 2024-2025 | Gocovri, Apokyn |
| Ucb, INC. | $231.57 | 2019-2025 | Nayzilam, Briviact |
| Amgen INC. | $218.14 | 2019-2024 | Uplizna |
| Allergan, INC. | $210.49 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $205.24 | 2020-2025 | Austedo Xr, Austedo Xr |
| Horizon Therapeutics Plc | $188.24 | 2022-2023 | Uplizna |
| Sk Life Science, INC. | $178.77 | 2022-2025 | Xcopri |
| Pfizer INC. | $155.30 | 2023-2025 | |
| Boston Scientific Corporation | $145.27 | 2023 | Watchman Access System |
| Neurocrine Biosciences, INC. | $142.76 | 2022-2025 | Ongentys, Ingrezza |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bassel Salem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.